A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

Conclusion.Selinexor was fairly well tolerated in patients with advanced TNBC but did not result in objective responses. However, clinical benefit rate was 30%, and further investigation of selinexor in this patient population should focus on combination therapies.

Source: The Oncologist - July 16, 2019 Category: Cancer & Oncology Authors: Michael Shafique, Roohi Ismail-Khan, Martine Extermann, Dan Sullivan, Dawn Goodridge, David Boulware, Deanna Hogue, Hatem Soliman, Hung Khong, Hyo S. Han Tags: Breast Cancer, Chinese Edition, Clinical Trial Results Source Type: research